Compare Ascendis Pharma A/S (ASND) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Meta Platforms Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Meta Platforms Inc trades at $669.1 (market cap $1.70T). The key difference: Meta Platforms Inc is far larger — about 95.8× Ascendis Pharma A/S's market cap, and Meta Platforms Inc pays a 0.31% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | META | |
|---|---|---|
Market Cap | $17.74B | $1.70T |
Sector | Health | Media |
52-Week High | $277.18 | $790.00 |
52-Week Low | $163.32 | $525.72 |
Enterprise Value | $18.11B | $1.70T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Meta Platforms (META) trades at $669.21, up 5.97% in the last 24 hours, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $201B and net income of $60.5B, maintaining high profitability margins. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $7.31 exceeding expectations of $6.70.
Outlook remains positive with analyst consensus price target of $820.94 representing 22.7% upside potential. Key risks include ongoing regulatory litigation and high capital expenditures for AI infrastructure. The stock trades at reasonable valuations with P/E of 24.33 and P/S of 7.99, supported by strong institutional ownership and 79% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
